

**American College of Emergency Physicians
Clinical Policies Committee Meeting
August 21, 2024
Zoom Meeting**

MINUTES

Participants

Committee members participating in all or part of the meeting: Deborah B. Diercks, MD, MSc, FACEP, Chair; John D. Anderson, MD, FACEP; Christopher R. Carpenter MD, MSc, FACEP; Benjamin W. Friedman, MD, FACEP, Methodologist; Seth R. Gemme, MD, FACEP; Charles J. Gerardo, MD, MHS, FACEP; Steven A. Godwin, MD, FACEP; Benjamin W. Hatten, MD, MPH, FACEP; Jason Haukoos, MD, FACEP, Methodologist; Sharon E. Mace, MD, FACEP, FAAP; Kaushal H. Shah, MD, FACEP; Richard D. Shih, MD, FACEP; Michael D. Smith, MD, MBA, FACEP; John T. Thompson, MD, EMRA Representative; Stacy A. Trent, MD, MPH, Methodologist; Lauren M. Westafer, DO, MPH, MS, FACEP; Yanling Yu, PhD, Advocate for Patient Safety.

Also present for all or part of the meeting: Caitlin Bonney, MD, Writing Committee on Cannabis; Travis Schulz, MLS, AHIP.

Agenda

1. Welcome and Introductions
2. Disclosures Pertinent to the Agenda
3. Open Comments for Asymptomatic Hypertension Clinical Policy
4. Board Feedback on Psychiatric Patient Clinical Question
5. Cannabis Guideline Draft Review

Major Points Discussed

1. Welcome and introductions

Dr. Diercks welcomed everyone to the meeting. Participants introduced themselves.

2. New disclosures pertinent to the agenda

There were no new disclosures pertinent to the agenda.

3. Open comments for Asymptomatic Hypertension Clinical Policy

Dr. Gemme led the committee members in the discussion of the public comments received on the asymptomatic hypertension clinical policy. Recommendations for additions or modifications to the draft were discussed. Edits will be made based on this input and responses to reviewers will be sent.

4. Board Feedback on Psychiatric Patient Clinical Question

Dr. Carpenter led the discussion on the feedback from the ACEP Board of Directors on the proposed clinical question for the psychiatric patient clinical policy. Based on the feedback, the committee made minor edits to the question for clarity.

5. Cardiovascular Effects of Cannabis Draft

Dr. Hatten led the committee members in the discussion of the draft of cannabis guideline. This guideline is the first guideline in the fulfillment of Resolution 50(21) Complications of Marijuana Use. Committee members suggested several edits to the draft. The writing committee will incorporate the revisions into the draft, and it will be presented to the Clinical Policies Committee for further review.